Based on the key indicators related to Recursion Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Recursion Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Recursion Pharmaceuticals' Non Currrent Assets Other are fairly stable compared to the past year. Long Term Debt is likely to rise to about 20 M in 2025, whereas Net Debt is likely to drop (510.2 M) in 2025. Key indicators impacting Recursion Pharmaceuticals' financial strength include:
The essential information of the day-to-day investment outlook for Recursion Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Recursion Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Recursion Pharmaceuticals.
Please note, the imprecision that can be found in Recursion Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Recursion Pharmaceuticals. Check Recursion Pharmaceuticals' Beneish M Score to see the likelihood of Recursion Pharmaceuticals' management manipulating its earnings.
Recursion Pharmaceuticals Stock Summary
Recursion Pharmaceuticals competes with Absci Corp, Affimed NV, Sana Biotechnology, Relay Therapeutics, and Immix Biopharma. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Recursion Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 400 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Recursion Pharmaceuticals Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Recursion Pharmaceuticals. It measures of how well Recursion is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Recursion Pharmaceuticals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Recursion had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Recursion Pharmaceuticals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Recursion Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Recursion Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Recursion Pharmaceuticals competition to find correlations between indicators driving Recursion Pharmaceuticals's intrinsic value. More Info.
Recursion Pharmaceuticals is rated below average in return on equity category among its peers. It is rated fifth in return on asset category among its peers . At this time, Recursion Pharmaceuticals' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Recursion Pharmaceuticals' earnings, one of the primary drivers of an investment's value.
Recursion Pharmaceuticals Systematic Risk
Recursion Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Recursion Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Recursion Pharmaceuticals correlated with the market. If Beta is less than 0 Recursion Pharmaceuticals generally moves in the opposite direction as compared to the market. If Recursion Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Recursion Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Recursion Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Recursion Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Recursion Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Recursion Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Recursion Pharmaceuticals growth as a starting point in their analysis.
Recursion Pharmaceuticals March 25, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Recursion Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Recursion Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Recursion Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Recursion Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Recursion Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.